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Effects of phytohemagglutinin on humoral 
antibody response, 
delayed hypersensitivity, 
and homograft rejection 
!?ytohemagg!Udn;n (PHA), a mucopro-
tein derived from the red kidney bean, 
Phaseolu.s vulgaris, has erythroagglutinating 
and leukoagglutinating properties and stimu-
ulates the small lymphocytes of the periph-
eral blood to transform into large blast 
cells. f, S, 18, 18 When administered parenter-
ally, it can suppress the immune response in 
animals, if treatment is started several days be-
fore the antigenic stimulation. 7,8, 10, 12, U, 18, 10 
To our knowledge 6 studies have been 
reported concerning the effect of PHA on 
the survival of skin or renal homografts, with 
conflicting results.2, 3, s, 13, 1', 17 Calne and 
associates2 and Casciani and Cortesini3 
treated canine recipients of renal allografts 
solely with PHA and found a slight immuno-
suppressive activity; the effect was additive 
to that of azathioprine if the 2 agents were 
given together. Two of 4 publications con-
cerned with skin grafts in rodents and rabbits 
reported no detectable effect of PHA,s,1I 
but the other 2 claimed slight prolongation 
of skin viability.lS, IT 
In our laboratory the immunosuppressive 
qualities of a particular batch of PHA were 
evaluated by the ability of this agent to 
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blunt humoral antibody formation in rabbits, 
to suppress the development of delayed 
hypersensitivity reactions in guinea pigs, and 
to mitigate the rejection of renal homografts 
in dogs. In addition the effect of red cell 
absorption on the biologic activity of PHA 
was assessed. 
METHODS 
EJreet of absorption. The preparation and 
characteristics of this PHA batch* were 
described by Hurn,ll who reported that it 
was able to agglutinate both red and white 
blood cells. An attempt was made in the 
present study to remove the hemagglutinins 
by doubly absorbing 1 volume of reconsti-
tuted PHA solution with 1.5 volumes of 
packed canine red blood cells. On both 
occasions the mixture was incubated at 4° C. 
for 30 minutes. 
The effect of the procedure was quanti-
tated in 2 ways. The first was by measure-
ment of the hemagglutinin and leukoagglu-
tinin titers of the PHA solution before and 
*The desirabilitT of performin~ this studT __ ~K 
• Plted to 111 by Dr. Maurice LaadT of Bethesda, Mel. He 
.Iso •• isted in fol'lll1llatins the esperimental protoc:al. 
The PHA used, PhTtoclin Balda E313, _ obtaiaed by 
Dr. Georp Hitchinp from the tel~ a-n:h Labor-
ataries, Beckealtam, EftIIaad. The dairatad PH" __ 
..-titlded by addiIIa' 1 mL IlOl1IIII ..... to 10 l1li. 
ot the powder before _ 
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after absorption with red blood cells, making 
use of standard twofold dilution techniques. 
For both examinations 0.1 ml. reconstituted 
PHA was the original volume from which 
dilution was begun; 0.1 ml. of a 2 percent 
suspension of triply washed canine red blood 
cells or, alternatively, 0.1 ml. of a canine leu-
kocyte suspension (corrected to 5,000 per 
cubic millimeter) was added at each dilution 
and the presence of agglutination determined 
microscopically. 
Second, both the absorbed and unabsorbed 
PHA solutions were tested for their mito-
genic effect on the lymphocytes of human 
peripheral blood. Human instead of canine 
white blood cells were used because they are 
so much more easily grown in culture. The 
cultures were adjusted to contain lOG lymph-
ocytes and various doses of the PHA solution 
were instilled. After 69 hours, 3H-thymidine 
(2 poc per tube) was added. The cells were 
harvested 3 hours later. The results of thy-
midine uptake were expressed as mean counts 
per minute per tube. 
Tests of immunosuppression. 
Humoral antibody. Four rabbits of about 
2.5 kilograms were immunized with 1 ml. 
per kilogram of 20 percent sheep red blood 
cells (SRBC) intravenously on Day O. They 
were treated daily with 1 ml. per kilogram 
unabsorbed PHA intraperitoneally from Day 
-2 to Day 4. Another 4 rabbits of similar 
weight were immunized with the same 
amount of SRBC on Days 0 and 10 and 
were treated with PHA for 7 days starting 
on Day 8. As control animals 5 rabbits were 
immunized with SRBC on Days 0 and 10 
and received no treatment. In all 3 groups 
hemagglutinin titrations were performed 
every other day beginning Day -2. 
Delayed hypersensitivity. Twenty-five 
guinea pigs weighing 600 to 700 grams were 
immunized subcutaneously on Days 0 and 7 
with a 0.25 mg. water-in-oil suspension of 
killed tubercle bacilli.* Thirty-four days after 
the initial immunization, the guinea pigs 
were divided into 4 groups for single intra-
-nne otIMr CODtraI ........ _ i_Iated with • 
~ ; Iii. withoId .uw baben:le bKiIIi. n., 
ditl _ "- pariied proeeIa .... ~dftK 
peritoneal injections as follows: 5 animals, 
10 mg. unabsorbed PHA; 5 animals, 5 mg. 
unabsorbed PHA; 4 animals, 2.5 mg. un-
absorbed PHA; and 7 animals, 2.5 mg. ab-
sorbed PHA. A fifth group consisted of 4 
animals which were untreated control ani-
mals. 
Two days after the injections, each of the 
guinea pigs was challenged intracutaneously 
with 0.1 ml. of the standard strengths of 
purified protein derivatives (PPD). Indura-
tion at the PPD inoculation sites was mea-
sured after 24 to 48 hours. 
Canine renal transplantation. Pelvic renal 
transplantation was performed in adult un-
related mongrel donors and recipients with 
concomitant removal of both kidneys of the 
recipient. Five experiments were discarded 
because of vascular thromboses within the 
first 6 days. The animals had biweekly deter-
minations of the leukocyte count, peripheral 
smear, hematocrit, and BUN. At autopsy, 
the renal homograft, spleen, liver, lung, 
heart, and mesenteric lymph nodes were ex-
amined. In the test animals, the PHA was 
given subcutaneously each day beginning on 
Day -2 and continuing for at least 2 weeks 
in animals which survived that long. There 
were 4 experimental groups. Eleven animals 
received no treatment; 8 animals, 2.5 mg. per 
kilogram unabsorbed PHA per day; 6 ani-
mals, 2.5 mg. per kilogram absorbed PHA 
per day; and 6 animals, 5.0 mg. per kilogram 
absorbed PHA per day. 
RESULTS 
Effects of absorption. 
Titers. The unabsorbed PHA solution (10 
mg. per milliliter) had hemagglutinin and 
leukoagglutinin titen of 1 :256 and 1 :512. 
After double absorption with red blood cells, 
these declined to 1:8 and 1 :256, respectively. 
Mitogenic activity. The unabsorbed PHA 
killed all cells at a dose of 1 mg., whereas 
die same quantity of the absorbed material 
both killed and stimulated (Table I). In 
smaIler amounts (particularly well seen with 
0.001 mg.), the unabsorbed PHA was many 
times more potent in stimulating blast trans-
fonnation. Thus the absorption process had 
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Fig. 1. The suppressive effect of unabsorbed PHA on the hemagglutinin response of rabbit 
immunized intravenously with sheep red blood cens (SRBC). The result. in the 2 groups 
were pooled from 4 PHA-treated and 5 control animals. 
Table I. 'H-thymidine uptake of tissue-
cultured human peripheral lymphocytes 
Dos, of 
PHA in Conlrol Nonabsorb,d Absorb,d 
mr./lub, (e.p.m.) (e.p.m.) (e.p.m.) 
0 865 
1.0 87 24,690 
0.1 6,335 90,230 
0.01 76,950 118,780 
° 
1,070 
om 50,350 72,020 
0.001 58,760 4,700 
0.0001 1,645 1,245 
significantly reduced the mitogenic quality. 
Tests of immunosuppression. 
Humoral antibody. In the rabbits the un-
absorbed PHA suppressed but did not abolish 
the primary hemoagglutinin response to in-
travenous SRBC (Fig. 1). However, there 
was no effect whatever on the response to 
rechallenge when PHA was started 2 days 
before a supplementary dose of SRBC was 
given to a previously exposed animal. 
Delayed hypersensitivity. Unabsorbed PHA 
in single 10 and 5 mg. injections intraperi. 
toneally caused it. 60 percent mortality rate 
within 48 houn (Table II). With 2.5 mg.' 
no deaths occurred with either the absorbed 
or unabsorbed PHA. At all the PHA dose 
levels, the expression of delayed hypersensi-
tivity to tuberculin was blunted or blocked 
compared with that in the control animals 
Table II. The toxicity and immunosuppressive 
effect of PHA in guinea pigs previously 
immunized with killed tubercle bacilli 
Group 
10 mg.t 
5 mg.t 
2.5 mg.t 
2.5 mg.* 
Control animals 
48 hour 
morlalily 
rat, of 
PHA 
3/5 
3/5 
0/4 
0/7 
Fr'qu,ncy of positiv, 
PPD skin I,sts (int,r· 
m,diat, str,ngth)-
24 hours I 48 hours 
0/2 0/2 
0/2 0/2 
0/4 0/4 
0/7 0/7 
3/4 3/4 
*A positive aida test wu defined .. induratioD of 5 _. 
or greater At fun ,trensth PPD, 3 01 the 15 PHA·treated 
.nim.1t bad positive oia tatl .. did an 4 of the CODtrol 
.nimalt. 
tUnabiorbed. 
*AbIorbed. 
(Table II). There were no significant tuber-
culin reactions with the fint and second 
strength PPD injections, although 3 of the 
15 PHA-treated animals developed skin in. 
duration of 5 mm. or more at the site of 
the full strength PPD inoculation. 
Canine renal transplantation. The PHA 
was toxic. Anorexia, diarrhea (often bloody), 
and weight loss were seen in most of the 
.dogs. Some of the animals had remarkable 
swelling of the e.'ttremities in which the sub-
cutaneous injections were given. Anemia was 
almost universal (Fig. 2). AU the foregoing 
side effects were most severe and common in 
the dogs treated with unabsorbed PHA. 
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Table III. The effect of absorbed and unabsorbed PHA on survival after canine 
renal transplantation 
Survival Range 
Group No. of dogs (days) (days) p 
Control animal. 11 9.0 ± 1.7 (S.E.) 4 to 21 
2.5 mg./kg.* 8 16.3 ± 2.3 (S.E.) 8 to 27 < 0.01 
2.5 mg./kg.t 6 10.2 ± 1.3 (S.E.) 6 to 14 
5.0 mg./kg.t 6 25.4 ± 7.8 (S.E.) 5 to 52 <0.01 
·Unabeorbed. 
tAbeorbed. 
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- ABSORBED PHA OK~ mQ/kQ 
...- ABSORBED PHA ~ mQ/kQ 
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Fig. 2. The anemia seen in dogs subjected to renal homotransplantation and treated with 
either absorbed or unabsorbed PHA. Note that the hematocrit falls were most pronounced 
in the animals injected with unabsorbed PHA. The animals that contributed to each study 
group are the same as in Table III. 
Treatment with PHA invariably induced 
a leukocytosis in the pretransplantation 
period, with the appearance of immature 
forms of all cell types. After transplantation 
there was no significant difference in the 
lymphocyte counts in the control animals 
as compared with those treated with PHA. 
The results in these experiments are sum-
marized in Table III. At doses of 2.5 mg. 
per kilogram per day, the animals rcceiving 
the unabsorbed PHA had a si~nificantly pro-
longed survival (p < 0.0 t) whr.reas dIOse 
treated with the absorbed material did not. 
The best results were with 5 mg. per kilo-
gram -per day of absorbed PHA (Table III). 
It was necessary to stop the injections in 3 
dogs in the latter group 16, 23, and 32 days 
after transplantation because of a shortage 
of PHA. The dogs died of uremia 17,29, and 
8 days later (Fig. 3). On histologic exam-
ination, there were no distinguishing features 
of the homografts retrieved from the treated 
dogs as compared with those from the con-
trol animals. Both had classical evidence of 
rejection. 
In the spleens of the animals treated with 
PHA, there was generally a reduced cellu-
larity in the red pulp. Contrary to what has 
been reported in mice,9 the white pulp was 
not hyfX'rplastic and, if anything, st'cmcd 
reduced in mass; this was particularly true if 
unabsorbed PHA had been given. 
• Extramedullary hematopoiesis in both the 
spleen -and liver was common in the PHA-
treated animals, especially prominently in 
those which had received the unabsorbed 
ma.terial and had developed severe ane-
mia. Mild intrahepatic cholestasis was pres-
.'of" , 
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Fig. 3. The coune of a dog after a renal homotransplantation from a non related mongrel 
donor. Treatment was with 5 mg. per kilogram per day absorbed PHA; injections were 
stopped after 23 days. The dog d~loped rejection and died 52 days after operation. Note 
the progressive anemia and weight lOIS. 
ent in the livers of several of the same 
dogs. 
The most disquieting extrarenal finding 
was myocardial necrosis in 3 of the 12 PHA· 
treated animals from which the heart was 
examined histologically. The infarctions were 
of moderate size, were not transmural, and 
appeared to be 3 or 4 days old. The signifi. 
cance of these abnormalities is obscured by 
the fact that similar lesions can be caused 
in dogs by other kinds of trauma.20 
DISCUSSION 
The results of the present study add to 
the growing body of evidence that PHA is 
an immunosuppressive agent of intermediate 
effectiveness. Its ability to suppress a hu· 
moral antibody response has been most 
widely accepted7• 8. 10. 11. 11. 18 and· has bE~en 
confirmed ill our experiments. The striking 
way in which PHA partially or completely 
prevents the expression of a pre.existing state 
of delayed hypersensitivity has not been gen-
erally appreciated, the only other description 
of this effect being that of Stevens and Wil-
loughby.l1 
Unfortunately, the side effects of the rela-
tively unrefined PHA used in the present 
study were too severe to permit its use in 
clinical medicine. A number of deaths were 
caused in average.sized guinea pigs with a 
single intraperitoneal injection of 5 or 10. 
mg. In dogs given 2.5 or 5 mg. per kilogram, 
severe local reactions at the sites of injection 
were common. With continued treatment 
the animals became clinically ill. Anemia 
was often severe. 
Hope that an improved PHA might be 
developed derives from the fact that some 
of the toxic properties can be largely reo 
moved by simple absorption technique. The 
investigations of Barkhan and Ballas1 sug· 
gested that the leukoagglutinating and hem-
agglutinating activities of PHA were not 
closely interrelated. This observation was 
exploited in the present experiments by abo 
sorbing most of the hemagglutinating prop· 
erties with red blood cells. 
In doing so, there was a concomitant 10!oS 
of some of the leukoagglutinating and mito-
genic potential of the PHA solution as 
judged by both in vitro and in vivo testing. 
This necessitated upward dose adjustments 
in the transplantation experiments. Never-
theless, the absorbed PHA seemed to have 
an improved therapeutic index. 
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SUMMARY 
Phytohemagglutinin (PHA) has been 
shown to inhibit the hemagglutinin response 
of rabbits to intravenous sheep red blood 
celis, to suppress the expression of pre-
existing tuberculin sensitivity in guinea pigs, 
and to prolong the functional survival of 
renal homograft in dogs. Concomitant with 
these desired effects are a number of side 
reactions; sudden death can be caused in 
guinea pigs and in dogs, and anemia and 
wasting can be induced. The toxicity of PHA 
can be partly reduced by preliminary ab-
sorption with red cells. 
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